| Type | Title | Date Released | |
|---|---|---|---|
6-K | Alpha Tau Ordinary Shares Included in Tel Aviv Stock Exchange TA-90 and TA-125 Indices | ||
6-K | Alpha Tau and Samsung Medical Center Sign MOU for Potential Pancreatic Cancer Clinical Trial in South Korea | ||
6-K | Alpha Tau Announces FDA Approval to Expand Alpha DaRT U.S. Recurrent Glioblastoma REGAIN Trial and Upcoming Presentation at SNO 2026 Annual Meeting | ||
6-K | Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study | ||
4 | Levy Raphi (Reporting) | ||
144 | Form 144 | ||
4 | Levy Raphi (Reporting) | ||
6-K | Alpha Tau Medical Ltd. Reports Financial Results for the Six Months Ended June 30, 2026 | ||
6-K | Alpha Tau Medical Announces Intent to Dual-List on the Tel Aviv Stock Exchange (TASE) | ||
6-K | Alpha Tau Reports Positive Clinical Data for Alpha DaRT® in Combination with Pembrolizumab for Head and Neck Cancer | ||
6-K | Alpha Tau Successfully Treats First Immunocompromised Patient in ADMIRE Study | ||
4 | Levy Raphi (Reporting) |
